EGFR and malignant pleural mesothelioma: This particular TargomiR, MesomiR 1, mimics miR-16, which is targeted to Epidermal Growth Factor (EGFR)-expressing cancer cells via an EGFR-bispecific antibody and shows success treating malignant pleural mesothelioma and non-small-cell lung cancer [188].